acute lymphoblastic leukaemia

Oncology

Targeting blood cancers with high unmet need

When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

NICE backs consolidation use of Blincyto in leukaemia

NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.

News

window into laboratory with scientist hard at work

Autolus bags FDA approval for leukaemia cell therapy

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).

News

Iclusig gets FDA nod as frontline therapy for rare leukaemia

Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le

Oncology

ASCO 2023 – Warner Biddle

While ASCO 2023 didn’t have too much focus on cell therapies, because of their lack of impact so far on the solid tumour space, Kite, a Gilead company, did share new data on Yescarta for la

Targeting blood cancers with high unmet need

NICE backs NHS use of Autolus' leukaemia CAR-T

NICE backs consolidation use of Blincyto in leukaemia

Autolus bags FDA approval for leukaemia cell therapy

Iclusig gets FDA nod as frontline therapy for rare leukaemia

ASCO 2023 – Warner Biddle

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

acute lymphoblastic leukaemia

Editor's Picks